Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
S1806
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
- NCT03775265 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Deep
We haven't built an HCP commentary report on S1806 (atezolizumab, mitomycin and 3 more in Bladder Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on S1806 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 19 | |
| YouTube | 3 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Bladder Urothelial Carcinoma; Muscle Invasive Bladder Carcinoma; Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8
- Interventions
- Atezolizumab; Biopsy of Bladder; Cisplatin; Computed Tomography; Cystoscopy; Fluorouracil; Gemcitabine; Magnetic Resonance Imaging; Mitomycin; Quality-of-Life Assessment; Radiation Therapy; Survey Administration; Transurethral Resection of Bladder Tumor
- Arms
- Arm I (RT, chemotherapy) · Active comparator
- Arm II (RT, chemotherapy, atezolizumab) · Experimental
- Enrollment
- 475 (estimated)
- Primary outcomes
- Bladder intact event-free survival (BI-EFS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jun 3, 2019
- Primary completion
- Jun 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03775265 · updated Aug 28, 2026